Company profile for Qnovia

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Qnovia is a platform medtech and pharmaceutical company whose mission is to help save lives.We’ve created a novel inhaled drug delivery platform to effectively deliver a broad range of pharmaceuticals. Our disruptive drug delivery technology is more than a medical device; it is a technology platform with multiple applications that have the potential to affect the lives of billions. Our proprietary inhalation-based technol...
Qnovia is a platform medtech and pharmaceutical company whose mission is to help save lives.We’ve created a novel inhaled drug delivery platform to effectively deliver a broad range of pharmaceuticals. Our disruptive drug delivery technology is more than a medical device; it is a technology platform with multiple applications that have the potential to affect the lives of billions. Our proprietary inhalation-based technology addresses many of the limitations of traditional pharmaceutical drug delivery systems to improve patient outcomes.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2920 West Broad St. #243 Richmond, VA 23230
Telephone
Telephone
212-741-5106 X 216
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/qnovia-inc-announces-leadership-transition-and-strategic-appointments-to-support-uk-commercialization-strategy-302425126.html

PR NEWSWIRE
10 Apr 2025

https://www.prnewswire.com/news-releases/qnovia-inc-announces-first-patient-dosed-in-us-in-phase-1-study-for-respirx-nicotine-inhaler-as-a-prescription-smoking-cessation-therapy-302343020.html

PR NEWSWIRE
07 Jan 2025

https://www.prnewswire.com/news-releases/qnovia-inc-raises-16-million-in-series-b-financing-to-advance-lead-asset-respirx-nicotine-inhaler-as-a-prescription-smoking-cessation-therapy-302326459.html

PR NEWSWIRE
10 Dec 2024

https://www.prnewswire.com/news-releases/qnovia-inc-ceo-speaks-at-fda-and-nih-public-meeting-to-encourage-innovation-of-smoking-cessation-treatment-options-302280571.html

PR NEWSWIRE
21 Oct 2024

https://www.prnewswire.com/news-releases/qnovia-inc-announces-fda-clearance-of-ind-application-for-lead-asset-respirx-nicotine-inhaler-as-a-prescription-smoking-cessation-therapy-302263046.html

PR NEWSWIRE
01 Oct 2024

https://www.reuters.com/business/healthcare-pharmaceuticals/developers-vapes-migraine-asthma-will-need-win-over-sceptics-2024-08-09/

REUTERS
08 Aug 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty